The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Non-small cell lung cancer NSCLC market.
Non-small cell lung cancer Overview
NSCLC is the most common type of lung cancer accounted for approximately 85% of all lung cancers. However, NSCLC metastasizes to other organs slower in comparison to SCLC, and microscopically, SCLC is composed of much smaller cells. NSCLC is mainly subcategorized into adenocarcinomas, squamous cell carcinomas, large cell carcinomas and several other types that occur less frequently include adenosquamous carcinomas and sarcomatoid carcinomas.
Download sample report– NSCLC Market Report
Some of the key highlights of the NSCLC market report
- The United States had 227,875 incident cases of Lung Cancer in 2020, of which ~85%, i.e., 193,694 were NSCLC cancer patients.
- The highest number of NSCLC were estimated in the United States.
- The stage-specific diagnosed cases were observed to be approximately 25%, 7%, 21%, and 46% for Stage I, Stage II, Stage III, And Stage IV cases of NSCLC.
NSCLC Diagnosis
The diagnosis and staging of NSCLC are often done at the same time. The tests and procedures used in the diagnosis of NSCLC are Physical exam and history, Laboratory tests, Chest X-ray, CT scan, Sputum cytology, Thoracentesis, Fine-needle aspiration (FNA) biopsy of the Lung, Bronchoscopy, Thoracoscopy, Mediastinoscopy, Anterior Mediastinotomy, Lymph node biopsy, Molecular test, Immunohistochemistry, among others.
There are different types of treatment available for NSCLC; however, mainly 10 types of standard treatment are used, which include: Surgery, Radiation therapy, Chemotherapy, Targeted therapy, Immunotherapy, Laser therapy, Photodynamic therapy (PDT), Cryosurgery, Electrocautery, and Watchful waiting.
Chemotherapy is used to stop the growth of cancer cells, either by killing the cells or by stopping their division. Targeted therapy is a type of treatment that uses drugs or other substances to attack specific cancer cells. These therapies usually cause less harm to normal cells than chemotherapy or radiation therapy. Monoclonal antibodies and tyrosine kinase inhibitors are the two main types of targeted therapy being used to treat advanced, metastatic, or recurrent NSCLC. Immunotherapy is a type of treatment that uses the patients’ immune system to fight cancer. Radiation therapy uses high-energy x-rays or other types of radiations to kill cancer cells or keep them from developing.
NSCLC Market Insights
There are different types of treatment available for NSCLC; however, mainly 10 types of standard treatment are used, which include Surgery, Radiation therapy, Chemotherapy, Targeted therapy, Immunotherapy, Laser therapy, Photodynamic therapy (PDT), Cryosurgery, Electrocautery, and Watchful waiting.
To recommend a treatment option to a patient of NSCLC, several key factors are taken into consideration, such age of the patient, previous medical history, health status, and smoking history. Along with those, another essential factor to consider is the stage of cancer at the time of diagnosis. Staging is usually carried out twice: after clinical and radiological examinations; and after surgery, in the case of the surgically resected tumor. Furthermore, biological testing of the tumor is also crucial to understanding the presence of specific mutations.
NSCLC Market Dynamics
The dynamics of the NSCLC market is anticipated to change in the coming years owing to the improvement in the rise in number of healthcare spending across the world. Key players, such as AstraZeneca, Bristol-Myers-Squibb, AbbVie, Roche, Merck, Novartis, Pfizer, Takeda Pharmaceuticals, Eli lilly, Johnson & Johnson, Sanofi, GlaxoSmithKline, and others are involved in developing drugs for NSCLC.
Report sample report- NSCLC Market Outlook
Table of content
1. Key Insights
2. Executive Summary of NSCLC
3. SWOT Analysis of NSCLC
4. NSCLC: Market Overview at a Glance
6. Diagnosis of NSCLC
7. Epidemiology and Patient Population
8. EU-5 Epidemiology
9. Japan Epidemiology
11. Guideline of NSCLC
12. Unmet Needs of NSCLC
13. Key Endpoints in NSCLC Clinical Trials
14. Marketed Therapies
15. Emerging Therapies
16. Non-Small Cell Lung Cancer (NSCLC): Seven Major Market Analysis
17. PD-L1—Market Size
18. BRAF Mutation—Market Size
19. c-MET Mutation—Market Size
20. EGFR Mutation—Market Size
21. ALK-Mutation—Market Size
22. Market Access and Reimbursement of NSCLC Therapies
23. Market Drivers of NSCLC
24. Market Barriers of NSCLC
25. Appendix
26. DelveInsight Capabilities
27. Disclaimer
28. About DelveInsight
About DelveInsight
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Contact Us
Yash
info@delveinsight.com
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/